Economic evaluation of sorafenib in unresectable hepatocellular carcinoma

Brian I. Carr, Stuart Carroll, Noemi Muszbek, Kathleen Gondek

Research output: Contribution to journalArticlepeer-review


Background and Aim: A double-blind, randomized phase III trial of sorafenib in advanced hepatocellular carcinoma demonstrated that sorafenib significantly prolonged overall survival compared to placebo (median overall survival=10.7 months vs 7.9 months, P

Original languageEnglish
Pages (from-to)1739-1746
Number of pages8
JournalJournal of Gastroenterology and Hepatology
Issue number11
Publication statusPublished - 2010


  • Cost-effectiveness
  • Economic models
  • Hepatocellular carcinoma
  • Sorafenib

ASJC Scopus subject areas

  • Gastroenterology
  • Hepatology


Dive into the research topics of 'Economic evaluation of sorafenib in unresectable hepatocellular carcinoma'. Together they form a unique fingerprint.

Cite this